Chimerix Inc., of Durham, N.C., reported preclinical data showing direct-acting antiviral candidate CMX-521 had activity in vitro against all strains of norovirus tested. Results also showed a promising safety profile, with oral administration delivering the drug directly to target cells in the gut.